Exelixis (EXEL)
(Delayed Data from NSDQ)
$35.61 USD
+0.78 (2.24%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $35.62 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXEL 35.61 +0.78(2.24%)
Will EXEL be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for EXEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXEL
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
3 Reasons Growth Investors Will Love Exelixis (EXEL)
EXEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
Other News for EXEL
Exelixis director Poste sells 30,000 common shares
Exelixis general counsel Hessekiel sells 50,000 common shares
Exelixis general counsel Hessekiel sells 50,000 common shares
Exelixis director Poste sells 30,000 common shares
Biotech Alert: Searches spiking for these stocks today